Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Non-Current Deffered Revenue (2019 - 2025)

AVITA Medical (RCEL) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $290000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 10.49% year-over-year to $290000.0, compared with a TTM value of $290000.0 through Dec 2025, down 10.49%, and an annual FY2025 reading of $290000.0, down 10.49% over the prior year.
  • Non-Current Deffered Revenue was $290000.0 for Q4 2025 at AVITA Medical, down from $298000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $882000.0 in Q1 2022 and bottomed at $290000.0 in Q4 2025.
  • Average Non-Current Deffered Revenue over 4 years is $447875.0, with a median of $353000.0 recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue plummeted 56.69% in 2023, then fell 8.64% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $698000.0 in 2022, then crashed by 48.85% to $357000.0 in 2023, then decreased by 9.24% to $324000.0 in 2024, then fell by 10.49% to $290000.0 in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for RCEL at $290000.0 in Q4 2025, $298000.0 in Q3 2025, and $307000.0 in Q2 2025.